Under a tenth of individuals that would benefit from obesity jabs including Wegovy have access to them, caution the global health agency as it publishes its initial guidance on the drugs.
Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for broader and more equitable availability to this class of drugs.
According to projections, over two billion will be obese by 2030 unless action is taken.
"Our new guidelines acknowledges that obesity is a lifelong illness that can be managed with thorough and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are key hurdles to widespread access to the jabs that can assist patients in reducing substantial body mass, explains the organization.
Despite the present most favorable outlook, the production of these medications could only cover around 100 million people – under 10% of eligible patients, as stated by the WHO.
The recommendation encourages nations and manufacturers to expand access, by measures like voluntary licensing.
The intellectual property rights on a key compound – the primary component of a leading brand – is set to lapse in multiple nations in 2026.
The injections imitate a biological compound to reduce digestion speed, reduce hunger and increase satiety so people eat less.
Patients typically see weight reduction after several weeks of commencing the once-weekly jabs.
Evidence indicates people may put most of the weight back on after a year of discontinuing the medication, when their typical hunger return.
To be carrying excess weight increases your likelihood for developing medical conditions, such as diabetes, heart disease, brain attack, and some malignancies.
Obesity impacts individuals in every country and was linked to millions of deaths worldwide in 2024, per the WHO.
En passionerad livsstilsbloggare som älskar att dela enkla lösningar för en mer harmonisk vardag.
News
By Laura Miller
•
12 Sep 2026
News
By Laura Miller
•
12 Sep 2026
News
By Laura Miller
•
12 Sep 2026
News
By Laura Miller
•
12 Sep 2026
News
By Laura Miller
•
12 Sep 2026
News
By Laura Miller
•
12 Sep 2026